ArticleMolecular pain
Systemic curcumin administration mitigates neuropathic pain in a rat model of trigeminal neuralgia by suppressing TNF-α and pSTAT3 signaling.
Article in Molecular pain. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trigeminal neuralgia (TN) is a debilitating neuropathic facial pain disorder characterized by sudden, severe paroxysmal pain that markedly impairs quality of life. Although current pharmacological treatments provide pain relief, their adverse effects highlight the need for safer alternative therapies. Curcumin, a natural polyphenol, exhibits anti-inflammatory and neuroprotective properties with minimal side effects. In this study, we examined the impact of intraperitoneal curcumin administration on the trigeminal ganglia in a TN rat model induced by unilateral infraorbital nerve constriction (IONC). Behavioral tests revealed that curcumin significantly reduced mechanical hypersensitivity compared with vehicle-treated controls. Immunohistochemical analysis showed decreased expression of glial fibrillary acidic protein (GFAP) and activating transcription factor 3 (ATF3), established markers of satellite glial cell (SGC) activation and neuronal stress in the trigeminal ganglia. Furthermore, curcumin administration reduced tumor necrosis factor-α (TNF-α) expression and modulated phosphorylated signal transducer and activator of transcription 3 (pSTAT3) activity. These findings suggest that curcumin alleviates neuropathic pain by suppressing glial activation and pSTAT3-related pro-inflammatory signaling. Curcumin may therefore represent a promising potential therapeutic candidate for TN, warranting further investigation into its clinical applicability and underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.